{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:10:43Z","timestamp":1789168243352,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000926","name":"Leukaemia Foundation","doi-asserted-by":"publisher","award":["2000538"],"award-info":[{"award-number":["2000538"]}],"id":[{"id":"10.13039\/501100000926","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1159593"],"award-info":[{"award-number":["1159593"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007428","name":"Naito Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1038\/s41375-022-01794-9","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T18:03:28Z","timestamp":1671559408000},"page":"379-387","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9013-750X","authenticated-orcid":false,"given":"Mika","family":"Casey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3605-9576","authenticated-orcid":false,"given":"Kane","family":"Segawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0782-6951","authenticated-orcid":false,"given":"Soi Cheng","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-8878","authenticated-orcid":false,"given":"Muhamamed Bilal","family":"Sabdia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Nowlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basit","family":"Salik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1473-4702","authenticated-orcid":false,"given":"Carol","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clay","family":"Winterford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7421-7195","authenticated-orcid":false,"given":"Sally","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Madore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Dougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1000-5393","authenticated-orcid":false,"given":"Maher K.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6631-9028","authenticated-orcid":false,"given":"Kyohei","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,20]]},"reference":[{"key":"1794_CR1","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood. 2010;116:2040\u20135.","journal-title":"Blood."},{"key":"1794_CR2","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1182\/blood.2021013289","volume":"139","author":"M Shadman","year":"2022","unstructured":"Shadman M, Pasquini M, Ahn KW, Chen Y, Turtle CJ, Hematti P, et al. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood. 2022;139:1330\u20139.","journal-title":"Blood."},{"key":"1794_CR3","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","volume":"4","author":"L Vercellino","year":"2020","unstructured":"Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D\u2019Aveni-Piney M, et al. Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv. 2020;4:5607\u201315.","journal-title":"Blood Adv"},{"key":"1794_CR4","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","volume":"379","author":"R Advani","year":"2018","unstructured":"Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma. N Engl J Med. 2018;379:1711\u201321.","journal-title":"N Engl J Med"},{"key":"1794_CR5","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","volume":"27","author":"SM Ansell","year":"2021","unstructured":"Ansell SM, Maris MB, Lesokhin AM, Chen RW, Flinn IW, Sawas A, et al. Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2021;27:2190\u20139.","journal-title":"Clin Cancer Res"},{"key":"1794_CR6","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-021-03879-4","volume":"597","author":"RA Kamber","year":"2021","unstructured":"Kamber RA, Nishiga Y, Morton B, Banuelos AM, Barkal AA, Vences-Catal\u00e1n F, et al. Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis. Nature. 2021;597:549\u201354.","journal-title":"Nature."},{"key":"1794_CR7","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41568-019-0183-z","volume":"19","author":"M Feng","year":"2019","unstructured":"Feng M, Jiang W, Kim BYS, Zhang CC, Fu YX, Weissman IL. Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer. 2019;19:568\u201386.","journal-title":"Nat Rev Cancer"},{"key":"1794_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41590-017-0004-z","volume":"19","author":"AA Barkal","year":"2018","unstructured":"Barkal AA, Weiskopf K, Kao KS, Gordon SR, Rosental B, Yiu YY, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat Immunol. 2018;19:76\u201384.","journal-title":"Nat Immunol"},{"key":"1794_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41423-019-0306-1","volume":"17","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, Smyth MJ. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol. 2020;17:1\u201312.","journal-title":"Cell Mol Immunol"},{"key":"1794_CR10","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1038\/s41375-020-0811-3","volume":"34","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, Casey M, Oey H, Vari F, Stagg J, Gandhi MK, et al. Targeting an adenosine-mediated \u201cdon\u2019t eat me signal\u201d augments anti-lymphoma immunity by anti-CD20 monoclonal antibody. Leukemia. 2020;34:2708\u201321.","journal-title":"Leukemia."},{"key":"1794_CR11","doi-asserted-by":"publisher","first-page":"e108130","DOI":"10.15252\/embj.2021108130","volume":"40","author":"O Kepp","year":"2021","unstructured":"Kepp O, Bezu L, Yamazaki T, Di Virgilio F, Smyth MJ, Kroemer G, et al. ATP and cancer immunosurveillance. EMBO J. 2021;40:e108130.","journal-title":"EMBO J."},{"key":"1794_CR12","doi-asserted-by":"publisher","first-page":"694831","DOI":"10.3389\/fcell.2021.694831","volume":"9","author":"F Grassi","year":"2021","unstructured":"Grassi F, De Ponte Conti B. The P2X7 receptor in tumor immunity. Front Cell Dev Biol. 2021;9:694831.","journal-title":"Front Cell Dev Biol."},{"key":"1794_CR13","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","volume":"17","author":"B Allard","year":"2020","unstructured":"Allard B, Allard D, Buisseret L, Stagg J. The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol. 2020;17:611\u201329.","journal-title":"Nat Rev Clin Oncol"},{"key":"1794_CR14","doi-asserted-by":"publisher","first-page":"e000610","DOI":"10.1136\/jitc-2020-000610","volume":"8","author":"R Yang","year":"2020","unstructured":"Yang R, Elsaadi S, Misund K, Abdollahi P, Vandsemb EN, Moen SH, et al. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade. J Immunother Cancer. 2020;8:e000610.","journal-title":"J Immunother Cancer."},{"key":"1794_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41375-020-0788-y","volume":"35","author":"Y Nagate","year":"2021","unstructured":"Nagate Y, Ezoe S, Fujita J, Okuzaki D, Motooka D, Ishibashi T, et al. Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function. Leukemia. 2021;35:107\u201318.","journal-title":"Leukemia."},{"key":"1794_CR16","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1182\/blood.2020006540","volume":"136","author":"K Nakamura","year":"2020","unstructured":"Nakamura K, Smyth MJ, Martinet L. Cancer immunoediting and immune dysregulation in multiple myeloma. Blood. 2020;136:2731\u201340.","journal-title":"Blood."},{"key":"1794_CR17","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","volume":"123","author":"DW Scott","year":"2014","unstructured":"Scott DW, Wright GW, Williams PM, Lih CJ, Walsh W, Jaffe ES, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014;123:1214\u20137.","journal-title":"Blood."},{"key":"1794_CR18","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1182\/blood.2019000889","volume":"134","author":"AS Cristino","year":"2019","unstructured":"Cristino AS, Nourse J, West RA, Sabdia MB, Law SC, Gunawardana J, et al. EBV microRNA-BHRF1-2-5p targets the 3\u2019UTR of immune checkpoint ligands PD-L1 and PD-L2. Blood. 2019;134:2261\u201370.","journal-title":"Blood."},{"key":"1794_CR19","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1182\/bloodadvances.2022008118","volume":"6","author":"M Casey","year":"2022","unstructured":"Casey M, Tu C, Harrison SJ, Nakamura K. Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA. Blood Adv. 2022;6:5165\u201370.","journal-title":"Blood Adv"},{"key":"1794_CR20","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1182\/blood-2008-01-135160","volume":"112","author":"V Minard-Colin","year":"2008","unstructured":"Minard-Colin V, Xiu Y, Poe JC, Horikawa M, Magro CM, Hamaguchi Y, et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood. 2008;112:1205\u201313.","journal-title":"Blood."},{"key":"1794_CR21","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1182\/blood-2013-04-496216","volume":"122","author":"HB Cohen","year":"2013","unstructured":"Cohen HB, Briggs KT, Marino JP, Ravid K, Robson SC, Mosser DM. TLR stimulation initiates a CD39-based autoregulatory mechanism that limits macrophage inflammatory responses. Blood. 2013;122:1935\u201345.","journal-title":"Blood."},{"key":"1794_CR22","doi-asserted-by":"publisher","first-page":"e001341","DOI":"10.1136\/jitc-2020-001341","volume":"9","author":"C Li","year":"2021","unstructured":"Li C, Xu X, Wei S, Jiang P, Xue L, Wang J. Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer. J Immunother Cancer. 2021;9:e001341.","journal-title":"J Immunother Cancer."},{"key":"1794_CR23","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/bjc.2017.356","volume":"117","author":"S Aras","year":"2017","unstructured":"Aras S, Zaidi MR. TAMeless traitors: macrophages in cancer progression and metastasis. Br J Cancer. 2017;117:1583\u201391.","journal-title":"Br J Cancer"},{"key":"1794_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","volume":"47","author":"GJ Weiner","year":"2010","unstructured":"Weiner GJ. Rituximab: mechanism of action. Semin Hematol. 2010;47:115\u201323.","journal-title":"Semin Hematol"},{"key":"1794_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2147\/ITT.S305432","volume":"10","author":"M Casey","year":"2021","unstructured":"Casey M, Nakamura K. The cancer-immunity cycle in multiple myeloma. Immunotargets Ther. 2021;10:247\u201360.","journal-title":"Immunotargets Ther"},{"key":"1794_CR26","doi-asserted-by":"publisher","first-page":"eabd6167","DOI":"10.1126\/sciadv.abd6167","volume":"7","author":"CL Grandjean","year":"2021","unstructured":"Grandjean CL, Garcia Z, Lema\u00eetre F, Br\u00e9art B, Bousso P. Imaging the mechanisms of anti-CD20 therapy in vivo uncovers spatiotemporal bottlenecks in antibody-dependent phagocytosis. Sci Adv. 2021;7:eabd6167.","journal-title":"Sci Adv."},{"key":"1794_CR27","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","volume":"142","author":"MP Chao","year":"2010","unstructured":"Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142:699\u2013713.","journal-title":"Cell."},{"key":"1794_CR28","doi-asserted-by":"publisher","first-page":"4338","DOI":"10.1182\/bloodadvances.2021004203","volume":"5","author":"B Manfroi","year":"2021","unstructured":"Manfroi B, De Grandis M, Moreaux J, Tabruyn S, Mayol JF, Quintero M, et al. The microenvironment of DLBCL is characterized by noncanonical macrophages recruited by tumor-derived CCL5. Blood Adv. 2021;5:4338\u201351.","journal-title":"Blood Adv"},{"key":"1794_CR29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3324\/haematol.2014.113472","volume":"100","author":"S Riihij\u00e4rvi","year":"2015","unstructured":"Riihij\u00e4rvi S, Fiskvik I, Taskinen M, Vajavaara H, Tikkala M, Yri O, et al. Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial. Haematologica. 2015;100:238\u201345.","journal-title":"Haematologica."},{"key":"1794_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6208-x","volume":"19","author":"YL Li","year":"2019","unstructured":"Li YL, Shi ZH, Wang X, Gu KS, Zhai ZM. Tumor-associated macrophages predict prognosis in diffuse large B-cell lymphoma and correlation with peripheral absolute monocyte count. BMC Cancer. 2019;19:1049.","journal-title":"BMC Cancer"},{"key":"1794_CR31","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1111\/cas.14437","volume":"111","author":"R Kazama","year":"2020","unstructured":"Kazama R, Miyoshi H, Takeuchi M, Miyawaki K, Nakashima K, Yoshida N, et al. Combination of CD47 and signal-regulatory protein-\u03b1 constituting the \u201cdon\u2019t eat me signal\u201d is a prognostic factor in diffuse large B-cell lymphoma. Cancer Sci. 2020;111:2608\u201319.","journal-title":"Cancer Sci"},{"key":"1794_CR32","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1182\/bloodadvances.2021004618","volume":"6","author":"K Miyawaki","year":"2022","unstructured":"Miyawaki K, Kato K, Sugio T, Sasaki K, Miyoshi H, Semba Y, et al. A germinal center-associated microenvironmental signature reflects malignant phenotype and outcome of DLBCL. Blood Adv. 2022;6:2388\u2013402.","journal-title":"Blood Adv"},{"key":"1794_CR33","doi-asserted-by":"publisher","first-page":"e445","DOI":"10.1016\/S2352-3026(15)00150-7","volume":"2","author":"C Keane","year":"2015","unstructured":"Keane C, Vari F, Hertzberg M, Cao KA, Green MR, Han E, et al. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. Lancet Haematol. 2015;2:e445\u201355.","journal-title":"Lancet Haematol"},{"key":"1794_CR34","doi-asserted-by":"publisher","first-page":"e000186","DOI":"10.1136\/jitc-2019-000186","volume":"8","author":"D Allard","year":"2020","unstructured":"Allard D, Allard B, Stagg J. On the mechanism of anti-CD39 immune checkpoint therapy. J Immunother Cancer. 2020;8:e000186.","journal-title":"J Immunother Cancer."},{"key":"1794_CR35","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1073\/pnas.1616752114","volume":"114","author":"X Wang","year":"2017","unstructured":"Wang X, Qin W, Xu X, Xiong Y, Zhang Y, Zhang H, et al. Endotoxin-induced autocrine ATP signaling inhibits neutrophil chemotaxis through enhancing myosin light chain phosphorylation. Proc Natl Acad Sci USA. 2017;114:4483\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1794_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.celrep.2019.03.011","volume":"27","author":"S Zumerle","year":"2019","unstructured":"Zumerle S, Cal\u00ec B, Munari F, Angioni R, Di Virgilio F, Molon B, et al. Intercellular calcium signaling induced by ATP potentiates macrophage phagocytosis. Cell Rep. 2019;27:1\u201310.e4.","journal-title":"Cell Rep"},{"key":"1794_CR37","doi-asserted-by":"publisher","first-page":"1838036","DOI":"10.1080\/19420862.2020.1838036","volume":"12","author":"BN Spatola","year":"2020","unstructured":"Spatola BN, Lerner AG, Wong C, Dela Cruz T, Welch M, Fung W, et al. Fully human anti-CD39 antibody potently inhibits ATPase activity in cancer cells via uncompetitive allosteric mechanism. mAbs. 2020;12:1838036.","journal-title":"mAbs."},{"key":"1794_CR38","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.celrep.2019.04.091","volume":"27","author":"I Perrot","year":"2019","unstructured":"Perrot I, Michaud HA, Giraudon-Paoli M, Augier S, Docquier A, Gros L, et al. Blocking antibodies targeting the CD39\/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies. Cell Rep. 2019;27:2411\u201325.e9.","journal-title":"Cell Rep"},{"key":"1794_CR39","doi-asserted-by":"publisher","first-page":"e157431","DOI":"10.1172\/JCI157431","volume":"132","author":"H Zhang","year":"2020","unstructured":"Zhang H, Feng L, de Andrade Mello P, Mao C, Near R, Csizmadia E, et al. Glycoengineered anti-CD39 promotes anticancer responses by depleting suppressive cells and inhibiting angiogenesis in tumor models. J Clin Investig. 2022;132:e157431.","journal-title":"J Clin Investig."}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01794-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01794-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01794-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T11:11:18Z","timestamp":1675422678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01794-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,20]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1794"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01794-9","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,20]]},"assertion":[{"value":"30 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}